SCIPHER MEDICINE

Scipher Medicine and Kythera Labs Form Strategic Partnership to Advance Precision Medicine in Rheumatology

a month ago

• Scipher Medicine and Kythera Labs have partnered to integrate clinical and genomic data from Scipher's PrismRA® Test with Kythera's multi-source EHR and claims data, achieving a 98% match rate while maintaining privacy protection. • The collaboration aims to accelerate rheumatology treatment discovery by combining Scipher's industry-leading clinico-transcriptomic rheumatology data assets with Kythera's data transformation technology. • This partnership creates a bench-to-bedside bridge that will help uncover deeper insights into autoimmune diseases and advance the development of personalized therapies for patients.

Scipher Medicine Expands Precision Medicine Partnerships to Transform Rheumatoid Arthritis Treatment

5 months ago

• Scipher Medicine has formed strategic partnerships with OMNY Health and Atropos Health to integrate its PrismRA test data into larger healthcare networks, creating comprehensive clinico-transcriptomic datasets for autoimmune disease research. • The OMNY Health collaboration connects Scipher's genomic insights from over 40,000 rheumatoid arthritis patients with OMNY's EHR network covering 80 million patients, enabling more targeted therapy development and improved patient outcomes. • Through the Atropos Health partnership, Scipher's precision medicine diagnostic data will enhance the Atropos Evidence Network, allowing clinicians to generate real-world evidence in minutes for personalized rheumatoid arthritis treatment decisions.

Personalized Medicine Biomarkers Market Set to Reach $79.26 Billion by 2034, Driven by Precision Oncology and AI

6 months ago

• The global personalized medicine biomarkers market is projected to grow from $21.95 billion in 2024 to $79.26 billion by 2034, representing a CAGR of 13.7% as demand for precision healthcare solutions increases. • Treatment selection dominates the market with 50.2% share, while oncology leads indication segments at 36.0%, reflecting the critical role of biomarkers in matching patients to targeted cancer therapies. • North America currently holds 52.0% of market share, with the U.S. market alone expected to grow at 15.5% CAGR to reach $40.90 billion by 2034, driven by technological advancements and regulatory support.

Sarilumab Facilitates Steroid Tapering More Effectively Than Methotrexate in Polymyalgia Rheumatica

6 months ago

• A recent study presented at ACR Convergence 2024 indicates sarilumab is more effective than methotrexate in helping polymyalgia rheumatica (PMR) patients discontinue steroid use. • The study found that 59% of PMR patients on sarilumab could discontinue glucocorticoids within 6 months, compared to 35% on methotrexate. • Sarilumab-treated patients also required fewer days on steroids and a lower cumulative steroid dose compared to those treated with methotrexate. • These findings suggest sarilumab can minimize steroid-related toxicities in older PMR patients, offering an evidence-based treatment option.